{"name":"Holy Stone Healthcare Co., Ltd","slug":"holy-stone-healthcare-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-19","label":"Delzicol Phase 3 readout (Ulcerative Colitis (UC))","drug":"Delzicol","drugSlug":"delzicol","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-12-31","label":"Delzicol Phase 2 readout (Ulcerative Colitis, Fecal Microbiota Transplantation)","drug":"Delzicol","drugSlug":"delzicol","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"CA102N","genericName":"CA102N","slug":"ca102n","indication":"Other","status":"phase_2"},{"name":"Delzicol","genericName":"Delzicol","slug":"delzicol","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"CA102N","genericName":"CA102N","slug":"ca102n","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Delzicol","genericName":"Delzicol","slug":"delzicol","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNRmkzX2xPWUVJRW1STU5LVmhqNXdZbm91SWFFX2pla1NfX0NycmRiY3NlNmY5Y2Q3eEQ0aFJGTm0xcGdhQTFQdUxUVmdrOWdtM013VkFGN2lsbDBlNm9JTXBybzNQMURUeDA3S01CeHlaemNPNTZ6bTgzX1NkQ1ZoSDhiRGdpb0lQVnFNYl9lZmpoLUdYc19pdld4UTlZR2xMbXNMRmhEcTlJTWgtdnh1aURvOWdfS1FSODBwVElFVk5RSWNmNUE?oc=5","date":"2025-02-13","type":"pipeline","source":"The ASCO Post","summary":"Triplet Regimen Demonstrates Benefit in BRAF V600E–Mutant Metastatic Colorectal Cancer - The ASCO Post","headline":"Triplet Regimen Demonstrates Benefit in BRAF V600E–Mutant Metastatic Colorectal Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwJBVV95cUxNMVBaRmxTUlZYYlVWSDVjcTktZFljZjFfcE9VbDlMR29mYUNmdGhENU1KMTRoVG1NcnVtUVphMnJuMXB0V0tCb1ZGVFZIOVFPMDBjQ3NNTC1ETWdnOFJGTy12Y2VJM1VLbDZzYlQ0bmlGRlhBb0Y0dlpPZ2hwb213TW01Z1RETzBBTU9vbFdtcjhaZHdMZERpbWlRQ0dCa2c1SVB2MXVkWjJrSXk5V0Z4Z1VneTlreEFEX0h2dW54NGpnRGt0a29fLW5xZEZoMDg4V0dDRGhvMDV1Q3hmQTlNcmJieVBmTEdoRXlvZ0hvcXdqbDdFazdMSGEwSU4yQkFGdVg4R1Nla3lXQ19hOUtwX0lJZVlBLTFVQkpF?oc=5","date":"2024-07-15","type":"regulatory","source":"PR Newswire","summary":"SKYRIZI's Approval For Ulcerative Colitis Treatment Expands AbbVie's Portfolio Across Immune-mediated Inflammatory Diseases | DelveInsight - PR Newswire","headline":"SKYRIZI's Approval For Ulcerative Colitis Treatment Expands AbbVie's Portfolio Across Immune-mediated Inflammatory Disea","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9aTF9YUDB3ZG1GOHQtSTlZZW9sR0ttTVdfY2ZLTnhiamstWTJydUdEdl9SRENQS29MMmNXV2hqUUZ2V1IyVlFyWE9JaG8yOXIzY0pBd3oxdUpmVTFqSkc0?oc=5","date":"2022-08-23","type":"trial","source":"nature.com","summary":"Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial - nature.com","headline":"Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE1jYm5XaXNtbWZDLVo5ZkkwZFdHcEJYU0pPelZBOHdhakVDRWdMX21IR0llMXJrdmZsbG9oQ0ZmM2xfREsyNS15ZUh1SERlSUdhdDd4bG5Rek51RjBBMWFjZ3RLWDV4OHg5bklfVS1mTl9nMmIzN1dJ?oc=5","date":"2017-11-07","type":"pipeline","source":"CTech","summary":"Biotech Company Struggling to Convince Doctors to Treat Burns with Pineapples - CTech","headline":"Biotech Company Struggling to Convince Doctors to Treat Burns with Pineapples","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"phase_1":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}